Form 4: GeneDx Holdings CEO Sells Shares to Cover Tax Obligations After RSU Vesting
SEC Form 4 Filing
GeneDx Holdings CEO, Katherine Stueland, sold 1,657 shares of Class A Common Stock to cover tax obligations following the vesting of restricted stock units.
Summary
- Katherine Stueland, CEO of GeneDx Holdings Corp., engaged in transactions involving the company's Class A Common Stock on January 29, 2025.
- She acquired 3,874 shares through the vesting of restricted stock units (RSUs) at no cost.
- Following the vesting, she sold 1,657 shares at a weighted average price of $78.4828 per share to cover tax withholding obligations.
- The sales occurred in multiple transactions with prices ranging from $78.48 to $79.0497 per share.
- After these transactions, Stueland directly owns 3,937 shares of Class A Common Stock.
Sentiment
Score: 5
Explanation: The document reflects a routine transaction related to executive compensation and does not indicate any positive or negative sentiment about the company's performance.
Industry Context
This is a routine transaction for executives who receive stock-based compensation. It is common for executives to sell shares to cover tax obligations when RSUs vest.
Comparison to Industry Standards
- The sale of shares to cover tax obligations is a standard practice among executives in publicly traded companies.
- Many companies use RSUs as part of their compensation packages, and the vesting schedules and tax implications are generally similar across the industry.
- The price range of $78.48 to $79.0497 per share is within the expected range for a company of this type, but a more detailed analysis of the stock's performance would be needed to make a full comparison.
Stakeholder Impact
- The sale of shares by the CEO may have a minor impact on the stock price, but it is unlikely to be significant given the relatively small number of shares sold.
- The transaction is a normal part of executive compensation and should not have a material impact on other stakeholders.
Key Dates
| Date | Description |
|---|---|
| 04/29/2023 | 25% of the underlying shares of the RSU vested. |
| 04/29/2024 | Another 25% of the underlying shares of the RSU vested. |
| 01/29/2025 | Date of the RSU vesting and subsequent sale of shares. |
| 01/31/2025 | Date the SEC Form 4 was signed. |
Keywords
GeneDx Holdings, Katherine Stueland, Class A Common Stock, Restricted Stock Units, RSU, Tax Withholding, SEC Form 4, Insider Trading
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.